View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsValeo Pharma 将来の成長Future 基準チェック /26Valeo Pharmaの収益は成長。EPSは成長すると64.2%年率で予測されます。主要情報n/a収益成長率64.19%EPS成長率Pharmaceuticals 収益成長31.8%収益成長率20.9%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日17 Jun 2024今後の成長に関する最新情報Price Target Changed • Sep 13Price target decreased by 20% to CA$0.40Down from CA$0.50, the current price target is provided by 1 analyst. New target price is 515% above last closing price of CA$0.065. Stock is down 76% over the past year. The company is forecast to post a net loss per share of CA$0.27 next year compared to a net loss per share of CA$0.32 last year.Price Target Changed • Feb 05Price target decreased by 12% to CA$0.72Down from CA$0.82, the current price target is an average from 2 analysts. New target price is 179% above last closing price of CA$0.26. Stock is down 57% over the past year. The company is forecast to post a net loss per share of CA$0.21 next year compared to a net loss per share of CA$0.32 last year.Major Estimate Revision • Feb 05Consensus revenue estimates fall by 14%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CA$74.4m to CA$64.1m. Forecast losses increased from -CA$0.14 to -CA$0.19 per share. Healthcare industry in Canada expected to see average net income growth of 21% next year. Consensus price target reaffirmed at CA$0.82. Share price fell 21% to CA$0.26 over the past week.Major Estimate Revision • Sep 20Consensus EPS estimates fall by 23%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CA$61.3m to CA$57.6m. Losses expected to increase from CA$0.20 per share to CA$0.25. Healthcare industry in Canada expected to see average net income growth of 17% next year. Consensus price target down from CA$1.47 to CA$0.72. Share price fell 10% to CA$0.27 over the past week.Price Target Changed • Sep 16Price target decreased by 16% to CA$1.23Down from CA$1.47, the current price target is an average from 3 analysts. New target price is 357% above last closing price of CA$0.27. Stock is down 53% over the past year. The company is forecast to post a net loss per share of CA$0.24 next year compared to a net loss per share of CA$0.32 last year.Major Estimate Revision • Jul 06Consensus EPS estimates upgraded to CA$0.18 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CA$0.207 to -CA$0.183 per share. Revenue forecast steady at CA$61.2m. Healthcare industry in Canada expected to see average net income growth of 19% next year. Consensus price target of CA$1.48 unchanged from last update. Share price rose 5.3% to CA$0.40 over the past week.すべての更新を表示Recent updatesReported Earnings • Sep 14Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: CA$0.079 loss per share (further deteriorated from CA$0.077 loss in 2Q 2023). Revenue: CA$14.1m (up 4.2% from 2Q 2023). Net loss: CA$7.81m (loss widened 21% from 2Q 2023). Revenue missed analyst estimates by 8.8%. Earnings per share (EPS) also missed analyst estimates by 60%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.Price Target Changed • Sep 13Price target decreased by 20% to CA$0.40Down from CA$0.50, the current price target is provided by 1 analyst. New target price is 515% above last closing price of CA$0.065. Stock is down 76% over the past year. The company is forecast to post a net loss per share of CA$0.27 next year compared to a net loss per share of CA$0.32 last year.お知らせ • Sep 09Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024Valeo Pharma Inc. announced that they will report Q3, 2024 results After-Market on Sep 12, 2024お知らせ • Aug 07Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced Mr. Steve Saviuk will remain on the company’s board of directors and assume the role of Chairman. Mr. Richard J. MacKay will step down from his role of chairman of the board and will remain a board member.お知らせ • Jun 18Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer (CDO) and consequently he is stepping down from the Company's Board of Directors. As Valeo's new CDO, Mr. Moghaddam will lead the design and implementation of strategies to identify and negotiate with financial parties with a view to strengthening the Company's capital structure in order to finance the future growth and development of the Company. He will work directly with the senior management team to plan, review, and revise the company's development programs. Mr. Moghaddam will also support the development and growth of the business through building relationships in the industry, identifying both product and M&A opportunities. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.New Risk • Jun 17New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$9.2m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-CA$55m). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (CA$10.9m market cap, or US$7.89m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).Reported Earnings • Jun 16Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: CA$0.079 loss per share (further deteriorated from CA$0.077 loss in 2Q 2023). Revenue: CA$14.1m (up 4.2% from 2Q 2023). Net loss: CA$7.81m (loss widened 21% from 2Q 2023). Revenue missed analyst estimates by 8.8%. Earnings per share (EPS) also missed analyst estimates by 60%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.分析記事 • Jun 14Market Might Still Lack Some Conviction On Valeo Pharma Inc. (TSE:VPH) Even After 55% Share Price BoostThose holding Valeo Pharma Inc. ( TSE:VPH ) shares would be relieved that the share price has rebounded 55% in the last...お知らせ • Jun 06Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024Valeo Pharma Inc. announced that they will report Q2, 2024 results After-Market on Jun 13, 2024分析記事 • Apr 20Market Cool On Valeo Pharma Inc.'s (TSE:VPH) Revenues Pushing Shares 31% LowerTo the annoyance of some shareholders, Valeo Pharma Inc. ( TSE:VPH ) shares are down a considerable 31% in the last...New Risk • Apr 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$12.8m (US$9.49m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$8.1m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-CA$47m). Market cap is less than US$10m (CA$12.8m market cap, or US$9.49m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (17% increase in shares outstanding).お知らせ • Mar 22Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has joined the Company's Board of Directors. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.Reported Earnings • Mar 15First quarter 2024 earnings releasedFirst quarter 2024 results: Net income: (up CA$6.25m from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.New Risk • Mar 15New major risk - Revenue and earnings growthEarnings have declined by 50% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$21m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-CA$40m). Earnings have declined by 50% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (CA$19.2m market cap, or US$14.2m).お知らせ • Mar 08Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024Valeo Pharma Inc. announced that they will report Q1, 2024 results After-Market on Mar 14, 2024分析記事 • Mar 02Valeo Pharma Inc. (TSE:VPH) Stocks Pounded By 33% But Not Lagging Industry On Growth Or PricingThe Valeo Pharma Inc. ( TSE:VPH ) share price has softened a substantial 33% over the previous 30 days, handing back...お知らせ • Feb 27Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024.お知らせ • Feb 13Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company's Board of Directors and that Messrs. Michel Trudeau, Stuart Fowler, Didier Leconte and Ms. Tamara Close have all resigned from its Board of Directors. More about Robert Raich; Prior to establishing RaichLegal Inc, Robert Raich was a senior partner at Spiegel Sohmer Inc., a Montreal firm specializing in taxation law, where he served as managing partner for over 25 years. His areas of expertise include taxation advice for real estate transactions, advice to both purchasers and vendors in acquisitions and sales of businesses, corporate reorganizations, venture capital financing and charitable planning. Mr. Raich graduated from McGill University and was called to the Barreau du Quebec in 1976. He has been recognized on several occasions as one of the Best Lawyers in Canada in the fields of Taxation law and Law of Estates and Trusts in Canada and has been a frequent guest lecturer at McGill University Faculty of Law and tax conferences. More about Charles Bisaillon; Charles Bisaillon is an entrepreneurial-minded leader who loves rapidly scaling organizations in both wholesale & direct-to-consumer channels. Charles is currently President and owner of Airtek Ltée, a leading Canadian manufacturing company, established in Montreal Quebec since 1970. Charles is also the Chief Financial Officer Groupe J.B a residential, commercial & institutional construction company. Mr. Bisaillon graduated from l'École des sciences de la gestion, UQAM. He is a chartered professional accountant of Canada (CPA Canada).Price Target Changed • Feb 05Price target decreased by 12% to CA$0.72Down from CA$0.82, the current price target is an average from 2 analysts. New target price is 179% above last closing price of CA$0.26. Stock is down 57% over the past year. The company is forecast to post a net loss per share of CA$0.21 next year compared to a net loss per share of CA$0.32 last year.Major Estimate Revision • Feb 05Consensus revenue estimates fall by 14%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CA$74.4m to CA$64.1m. Forecast losses increased from -CA$0.14 to -CA$0.19 per share. Healthcare industry in Canada expected to see average net income growth of 21% next year. Consensus price target reaffirmed at CA$0.82. Share price fell 21% to CA$0.26 over the past week.Reported Earnings • Jan 30Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: CA$0.32 loss per share (further deteriorated from CA$0.32 loss in FY 2022). Revenue: CA$53.9m (up 94% from FY 2022). Net loss: CA$27.8m (loss widened 8.0% from FY 2022). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 12%. Over the last 3 years on average, earnings per share has fallen by 40% per year whereas the company’s share price has fallen by 38% per year.お知らせ • Jan 23Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024Valeo Pharma Inc. announced that they will report Q4, 2023 results After-Market on Jan 29, 2024分析記事 • Jan 17Investors Still Aren't Entirely Convinced By Valeo Pharma Inc.'s (TSE:VPH) Revenues Despite 68% Price JumpValeo Pharma Inc. ( TSE:VPH ) shares have continued their recent momentum with a 68% gain in the last month alone. Not...New Risk • Jan 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 17% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$35m). Negative equity (-CA$35m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Share price has been volatile over the past 3 months (17% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$23.2m market cap, or US$17.2m). Market cap is less than US$100m (CA$23.2m market cap, or US$17.2m).お知らせ • Nov 21Valeo Pharma Inc. Announces Chief Financial Officer ChangesValeo Pharma Inc. announced the appointment of Mr. Pascal Tougas to the position of Chief Financial Officer, effective November 20, 2023. Joining the Valeo leadership team, Mr. Tougas will succeed Luc Mainville, who is leaving the Company after 5 years to pursue other ventures. Pascal is a seasoned senior pharmaceutical executive with a strong finance profile. With a passion for driving value in organizations, Pascal has a track record of collaboration, forward strategic thinking, operational and financial business acumen, and execution. Pascal spent 11 years at Sanofi Canada in roles of increasing responsibility where he served as Country Head, Trade and Revenue Management, Chief Financial Officer Canada interim and Director Controlling and Operations Canada amongst others. Pascal holds a bachelor's degree in business administration from the HEC Montreal and a CPA designation.お知らせ • Nov 08Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of DirectorsValeo Pharma Inc. announced that Mr. Richard Lajoie has joined the Company's Board of Directors and that Ms. Maureen C. Brennan has retired from its Board of Directors. ichard Lajoie has been recognized over the last 24 years as an inspirational and creative leader with a strong capacity to build high performing teams. Richard was President of Bausch Health, Canada from 2017 to 2021 before being promoted to President Ortho Dermatologics US based in New Jersey. He has led innovative business model transformations, many new launches and completed successful business development deals. Prior to Bausch Health, Richard spent 12 years with Novartis Pharmaceuticals in roles of increasing responsibility (Sales, Marketing, Government Affairs and Medical) located in Montreal, Calgary and Copenhagen where he led Denmark, Norway and Iceland as General Manager for Novartis Oncology.New Risk • Oct 31New major risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: CA$13.8m (US$9.99m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Negative equity (-CA$35m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$13.8m market cap, or US$9.99m).New Risk • Oct 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$28m Forecast net loss in 1 year: CA$17m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-CA$35m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$16.8m market cap, or US$12.3m).Major Estimate Revision • Sep 20Consensus EPS estimates fall by 23%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CA$61.3m to CA$57.6m. Losses expected to increase from CA$0.20 per share to CA$0.25. Healthcare industry in Canada expected to see average net income growth of 17% next year. Consensus price target down from CA$1.47 to CA$0.72. Share price fell 10% to CA$0.27 over the past week.Price Target Changed • Sep 16Price target decreased by 16% to CA$1.23Down from CA$1.47, the current price target is an average from 3 analysts. New target price is 357% above last closing price of CA$0.27. Stock is down 53% over the past year. The company is forecast to post a net loss per share of CA$0.24 next year compared to a net loss per share of CA$0.32 last year.Reported Earnings • Sep 15Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: CA$0.069 loss per share (further deteriorated from CA$0.058 loss in 3Q 2022). Revenue: CA$14.1m (up 132% from 3Q 2022). Net loss: CA$5.84m (loss widened 23% from 3Q 2022). Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings.お知らせ • Sep 08Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023Valeo Pharma Inc. announced that they will report Q3, 2023 results After-Market on Sep 13, 2023お知らせ • Sep 01Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement QuébecValeo Pharma Inc. announced a non-brokered private placement of 13,999,997 units of the company at a price of CAD 0.28 per unit for gross proceeds of CAD 3,919,999 and entered into a loan agreement with a related party for a principal amount of CAD 580,000 bearing annual interest at a rate of 12%; for aggregate total gross proceeds of CAD 4,499,999 on August 31, 2023. The transaction included participation from Investissement Québec for CAD 2 million and insiders for CAD 1,421,000. Each unit consist of one class A share of the company and one-half share purchase warrant of the company. Each full warrant entitles the holder to purchase one share in the capital of the company at the price of CAD 0.35 per warrant share for a period of 60 months from the closing date of the transaction. In the event that the daily volume weighted average trading price of the shares over any ten consecutive trading days is greater or equal to CAD 0.70, the company may give notice to the warrant holder, at any time after the first 12 months following the closing, that all outstanding warrants must be exercised within a period of 30 days from the date of receipt of the notice, failing which the warrants will automatically expire. The common shares and the warrants are subject to a statutory 4 month hold period under the applicable securities laws.Major Estimate Revision • Jul 06Consensus EPS estimates upgraded to CA$0.18 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CA$0.207 to -CA$0.183 per share. Revenue forecast steady at CA$61.2m. Healthcare industry in Canada expected to see average net income growth of 19% next year. Consensus price target of CA$1.48 unchanged from last update. Share price rose 5.3% to CA$0.40 over the past week.Board Change • Jun 29Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Marc Leger was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 23Valeo Pharma Inc. Announces Board AppointmentsValeo Pharma Inc. announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the appointment of Ms. Close and Mr. Leconte, Valeo's Board of Directors is now comprised of 8 Directors, 5 of whom are independent. Ms. Close is a senior investment and Environmental, Social and Governance (ESG) professional with over 25 years of experience in capital markets, with roles spanning sell-side trading and institutional sales to buy-side research, risk management and strategy. She is the founder and managing partner of Close Group Consulting, an independent, boutique ESG advisory firm headquartered in Montreal, with offices in Toronto, Boston, and London (UK). Tamara is a sought-after speaker and regularly publishes ESG thought leadership and research. Ms. Close holds an M.Sc. Finance from Concordia University with a B.A. Economics from McGill University and is a Chartered Financial Analyst (CFA). Mr. Didier Leconte is a highly experienced investor and Canadian life sciences leader. He has deep commercial experience in Canada and Québec's technology transfer and investment arenas. With a strong dedication to the development of Québec's and Canada's life sciences industries, Didier served as Vice-president, Life Science & Technology for Investissement Quebec and Vice-president Life Sciences at Fonds de solidarité FTQ. Mr. Leconte holds a MBA, Technology Management & Innovation from the Université du Québec à Montréal, a certification in governance from Université Laval and an engineering degree in Material Sciences from École d'ingénieurs Sup Galilée, Institut Galilée, Université Sorbonne Paris Nord.Breakeven Date Change • Jun 17Forecast breakeven date pushed back to 2025The 4 analysts covering Valeo Pharma previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 85% per year to 2024. The company is expected to make a profit of CA$13.5m in 2025. Average annual earnings growth of 72% is required to achieve expected profit on schedule.Reported Earnings • Jun 15Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: CA$0.077 loss per share (further deteriorated from CA$0.063 loss in 2Q 2022). Revenue: CA$13.6m (up 184% from 2Q 2022). Net loss: CA$6.48m (loss widened 27% from 2Q 2022). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Jun 09Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023Valeo Pharma Inc. announced that they will report Q2, 2023 results After-Market on Jun 13, 2023分析記事 • Jun 08Valeo Pharma Inc. (TSE:VPH) Might Not Be As Mispriced As It Looks After Plunging 29%To the annoyance of some shareholders, Valeo Pharma Inc. ( TSE:VPH ) shares are down a considerable 29% in the last...Reported Earnings • Mar 17First quarter 2023 earnings: EPS misses analyst expectationsFirst quarter 2023 results: CA$0.077 loss per share (further deteriorated from CA$0.074 loss in 1Q 2022). Revenue: CA$13.2m (up 210% from 1Q 2022). Net loss: CA$6.25m (loss widened 6.6% from 1Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.7%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.Recent Insider Transactions Derivative • Mar 02Independent Director exercised options to buy CA$151k worth of stock.On the 27th of February, Vincent Hogue exercised options to buy 265k shares at a strike price of around CA$0.40, costing a total of CA$106k. This transaction amounted to 105% of their direct individual holding at the time of the trade. Since March 2022, Vincent has owned 252.41k shares directly. Company insiders have collectively bought CA$2.5b more than they sold, via options and on-market transactions, in the last 12 months.お知らせ • Feb 08Valeo Pharma Obtains Public Reimbursement for Onstryv in QuebecValeo Pharma Inc. announced that Onstryv (safinamide) for the treatment of patients suffering from Parkinson's disease, is now listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Quebec Régie de l'assurance maladie du Québec ("RAMQ"), effective February 1, 2023. Onstryv® is approved by Health Canada as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's Disease in patients experiencing "off" episodes. Onstryvâ is a prescription medication available at pharmacies across Canada in 50mg and 100mg tablets. Parkinson's Disease is a progressive neurological disease involving the loss of dopamine producing neurons in the brain. While tremors are the best known symptom, Parkinson's Disease also causes other symptoms including slowed movement, rigid muscles, impaired posture and balance, speech and writing difficulties. On a per capita basis, Canada has amongst the higher incidences of Parkinson's Disease in the world and the number of patients is expected to grow significantly over the next thirty years as the median population age increases. Safinamide, known as Onstryv® in Canada and Xadago® in the rest of the world, is a chemical entity with a unique mode of action including selective and reversible MAO-B inhibition. Clinical trials have established its efficacy in controlling motor symptoms and motor complications in the short term, maintaining this effect over 2 years. Results from 24 month double-blind controlled studies suggest that safinamide shows statistically significant effects on motor fluctuations (ON/OFF time) without increasing the risk of developing troublesome dyskinesia. Onstryv® is a once-daily dose and has no diet restrictions due to its high MAO-B/MAO-A selectivity.Major Estimate Revision • Feb 06Consensus EPS estimates fall by 31%The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -CA$0.17 per share expected, vs -CA$0.13 per share profit forecast previously. Revenue forecast reaffirmed at CA$64.5m. Healthcare industry in Canada expected to see average net income growth of 4.6% next year. Consensus price target of CA$1.63 unchanged from last update. Share price fell 6.3% to CA$0.59 over the past week.Reported Earnings • Feb 01Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: CA$0.32 loss per share (further deteriorated from CA$0.20 loss in FY 2021). Revenue: CA$27.7m (up 105% from FY 2021). Net loss: CA$25.7m (loss widened 81% from FY 2021). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 33%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.お知らせ • Jan 27Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 PatientsValeo Pharma Inc. announced that Health Canada has accepted for review Veru's New Drug Submission ("NDS-CV") for sabizabulin for COVID-19. Sabizabulin is a novel dual antiviral and anti-inflammatory agent being developed for the treatment of hospitalized moderate to severe COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS) and death. The Phase 3 COVID-19 clinical trial of sabizabulin was a double-blind, randomized, placebo controlled trial conducted in 204 hospitalized COVID-19 patients with moderate to severe COVID-19 (= WHO 4-supplemental oxygen) at high risk for ARDS and death. The primary endpoint was the proportion of deaths by Day 60. Patients in both treatment groups were allowed to receive standard of care treatment, including remdesivir, dexamethasone, anti-IL6 receptor antibodies and JAK inhibitors. Based on a planned interim analysis of the first 150 patients randomized, the Independent Data Monitoring Committee unanimously recommended to halt the study early for clear clinical efficacy and no safety concerns were identified. Treatment with sabizabulin 9 mg once daily, an oral, first-in-class, new chemical entity, microtubule disruptor that has dual anti-inflammatory and antiviral properties, resulted in a clinically meaningful and statistically significant 55.2% relative reduction in deaths compared to placebo. The results of the interim analysis were published in The New England Journal of Medicine (NEJM) Evidence. In the final analysis of all 204 patients, sabizabulin demonstrated a statistically significant 51.6% relative reduction in deaths compared to placebo. Sabizabulin was well tolerated. Valeo previously announced in September 2022 that Veru and Valeo had entered into an agreement under which Valeo is the commercial partner for Veru's product candidate sabizabulin for COVID-19 in Canada.お知らせ • Jan 26Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023Valeo Pharma Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 30, 2023お知らせ • Nov 22Valeo Pharma Inc. Announces Stepping Down of Frederic Fasano as President and Chief Operating OfficerValeo Pharma Inc. announced that Mr. Frederic Fasano has stepped down as Valeo's President and Chief Operating Officer. Mr. Fasano will continue to act as special advisor to the Company and will remain on the Board of Directors. Mr. Fasano's duties and responsibilities are being integrated and assumed by the Company's CEO, Steve Saviuk and its Chief Commercial Officer, Mr. Kyle Steiger.お知らせ • Nov 16+ 1 more updateValeo Pharma Inc. Revises Revenue Guidance for the Fourth Quarter of 2022Valeo Pharma Inc. revised revenue guidance for the fourth quarter of 2022. The company has raised revenue guidance for its fourth quarter of 2022 to $12.5 - $13.0 million, an increase of 14% to 18% over previously issued guidance of $11 million.Price Target Changed • Nov 16Price target increased to CA$1.63Up from CA$1.33, the current price target is an average from 3 analysts. New target price is 159% above last closing price of CA$0.63. Stock is down 18% over the past year. The company is forecast to post a net loss per share of CA$0.25 next year compared to a net loss per share of CA$0.20 last year.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Michel Trudeau was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 16Valeo Pharma Inc. Provides Revenue Guidance for the Fourth Quarter of 2022Valeo Pharma Inc. provided revenue guidance for the fourth quarter of 2022. The company expects revenues in the fourth quarter to exceed $11 million.Reported Earnings • Sep 14Third quarter 2022 earnings: EPS misses analyst expectationsThird quarter 2022 results: CA$0.058 loss per share (further deteriorated from CA$0.042 loss in 3Q 2021). Revenue: CA$6.07m (up 7.2% from 3Q 2021). Net loss: CA$4.74m (loss widened 60% from 3Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.お知らせ • Sep 10Valeo Pharma Inc. to Report Q3, 2022 Results on Sep 13, 2022Valeo Pharma Inc. announced that they will report Q3, 2022 results After-Market on Sep 13, 2022お知らせ • Aug 31Valeo Pharma Announces Executive AppointmentsValeo Pharma Inc. announced the appointment of Mr. Kyle Steiger to the role of Senior Vice-President and Chief Commercial Officer ("CCO"). Mr. Steiger is a pharmaceutical industry veteran whose diverse work experience includes specialty pharma, biologics, primary care, medical devices, OTC, health policy and market access. He spent nearly 20 years at Novartis Canada in various executive positions including Franchise Head Hematology, Vice-President Primary Care and most recently Vice-President Ophthalmology. Valeo also announced that Mr. Jean-François Fournier has joined as its new Business Unit Head – Ophthalmology. Prior to joining Valeo, Jean-François served as Commercial Director – Marketing & Sales at Novartis Canada.分析記事 • Jun 24Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%The analysts covering Valeo Pharma Inc. ( TSE:VPH ) delivered a dose of negativity to shareholders today, by making a...Major Estimate Revision • Jun 21Consensus revenue estimates fall by 24%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from CA$36.0m to CA$27.3m. Forecast losses increased from -CA$0.17 to -CA$0.23 per share. Healthcare industry in Canada expected to see average net income growth of 6.8% next year. Consensus price target down from CA$1.70 to CA$1.33. Share price rose 19% to CA$0.62 over the past week.Recent Insider Transactions • Jun 19Key Executive recently bought CA$113k worth of stockOn the 16th of June, Richard MacKay bought around 217k shares on-market at roughly CA$0.52 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$816k worth in shares.分析記事 • Jun 17Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their ForecastsIt's been a pretty great week for Valeo Pharma Inc. ( TSE:VPH ) shareholders, with its shares surging 12% to CA$0.56 in...Breakeven Date Change • Jun 17No longer forecast to breakevenThe 3 analysts covering Valeo Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CA$2.96m in 2023. New consensus forecast suggests the company will make a loss of CA$1.82m in 2024.Reported Earnings • Jun 15Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: CA$0.063 loss per share (down from CA$0.028 loss in 2Q 2021). Revenue: CA$4.77m (up 80% from 2Q 2021). Net loss: CA$5.10m (loss widened 173% from 2Q 2021). Revenue missed analyst estimates by 27%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 204%, compared to a 22% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Jun 09Valeo Pharma Inc. to Report Q2, 2022 Results on Jun 14, 2022Valeo Pharma Inc. announced that they will report Q2, 2022 results After-Market on Jun 14, 2022Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Michel Trudeau was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Apr 27Price target decreased to CA$1.70Down from CA$1.87, the current price target is an average from 3 analysts. New target price is 227% above last closing price of CA$0.52. Stock is down 56% over the past year. The company is forecast to post a net loss per share of CA$0.17 next year compared to a net loss per share of CA$0.20 last year.Major Estimate Revision • Mar 31Consensus EPS estimates fall by 42%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CA$38.1m to CA$36.0m. Losses expected to increase from CA$0.12 per share to CA$0.17. Healthcare industry in Canada expected to see average net income growth of 5.0% next year. Consensus price target of CA$1.70 unchanged from last update. Share price fell 4.4% to CA$0.65 over the past week.Recent Insider Transactions Derivative • Mar 12Key Executive exercised options to buy CA$1.5m worth of stock.On the 4th of March, Richard MacKay exercised options to buy 3m shares at a strike price of around CA$0.40, costing a total of CA$1.0m. This transaction amounted to 30% of their direct individual holding at the time of the trade. Since March 2021, Richard's direct individual holding has increased from 8.15m shares to 8.76m. Company insiders have collectively bought CA$2.5m more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CA$0.20 loss per share (down from CA$0.082 loss in FY 2020). Revenue: CA$13.6m (up 82% from FY 2020). Net loss: CA$14.2m (loss widened 199% from FY 2020). Revenue missed analyst estimates by 7.1%. Over the next year, revenue is forecast to grow 174%, compared to a 33% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.お知らせ • Feb 26Valeo Pharma Inc., Annual General Meeting, Apr 27, 2022Valeo Pharma Inc., Annual General Meeting, Apr 27, 2022.お知らせ • Feb 22Valeo Pharma Inc. to Report Q4, 2021 Results on Feb 28, 2022Valeo Pharma Inc. announced that they will report Q4, 2021 results After-Market on Feb 28, 2022Price Target Changed • Jan 12Price target decreased to CA$1.77Down from CA$1.97, the current price target is an average from 3 analysts. New target price is 145% above last closing price of CA$0.72. Stock is down 43% over the past year. The company is forecast to post a net loss per share of CA$0.15 next year compared to a net loss per share of CA$0.082 last year.お知らせ • Jan 06Valeo Pharma's Hespercotm Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted for PublicationValeo Pharma Inc. announced that Hesperco, its unique flavonoid formulation approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw's banners including Loblaws, Dominion, Zehrs, Fortinio's, Your Independent Grocer and Superstore.お知らせ • Nov 25Valeo Pharma Inc. announced that it expects to receive CAD 20 million in funding from Investissement Québec, Investment Arm and other investorsValeo Pharma Inc. announced a bought deal private placement of 10,000 convertible unsecured debentures at a price of CAD 1,000 per debenture for gross proceeds of CAD 10,000,000 and private placement of 10,000 convertible unsecured debentures at a price of CAD 1,000 per debenture for gross proceeds of CAD 10,000,000 to Investissement Québec, Investment Arm for aggregate gross proceeds of CAD 20,000,000 on November 24, 2021. The debentures are being issued at par. The debentures will mature on December 31, 2024 and will accrue interest at the rate of 12% per annum, payable quarterly beginning on March 31, 2022. At the holders' option, the debentures may be converted into common shares of the company at any time and from time to time, up to the maturity date, at a conversion price of CAD 1.15 per common share. The company has granted the underwriters an option to purchase up to an additional CAD 1,500,000 aggregate principal amount of debentures, exercisable at any time up to 48 hours prior to the closing. The closing is expected to occur on or about December 9, 2021 and is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange. The company will use commercially reasonable efforts to list the debentures on the Canadian Securities Exchange. The debentures and any common shares issuable upon conversion thereof will be subject to a statutory hold period lasting four months and one day following the closing date.Recent Insider Transactions • Oct 23Key Executive recently bought CA$90k worth of stockOn the 20th of October, Richard MacKay bought around 100k shares on-market at roughly CA$0.90 per share. In the last 3 months, they made an even bigger purchase worth CA$360k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$703k worth in shares.Recent Insider Transactions • Oct 08Key Executive recently bought CA$75k worth of stockOn the 1st of October, Richard MacKay bought around 100k shares on-market at roughly CA$0.75 per share. In the last 3 months, there was an even bigger purchase from another insider worth CA$100k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$253k worth in shares.Recent Insider Transactions • Oct 02Key Executive recently bought CA$78k worth of stockOn the 27th of September, Richard MacKay bought around 109k shares on-market at roughly CA$0.72 per share. In the last 3 months, there was an even bigger purchase from another insider worth CA$100k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$178k worth in shares.Reported Earnings • Sep 24Third quarter 2021 earnings released: CA$0.042 loss per share (vs CA$0.028 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: CA$5.67m (up 280% from 3Q 2020). Net loss: CA$2.97m (loss widened 84% from 3Q 2020).Recent Insider Transactions • Jul 18Senior VP & CFO recently bought CA$100k worth of stockOn the 15th of July, Luc Mainville bought around 150k shares on-market at roughly CA$0.67 per share. In the last 3 months, they made an even bigger purchase worth CA$200k. Luc has been a buyer over the last 12 months, purchasing a net total of CA$316k worth in shares.お知らせ • Jul 15Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™Valeo Pharma Inc. announced that Redesca™ and Redesca HP™, its low molecular weight heparin ("LMWH") biosimilar, is now covered for public reimbursement in 7 provinces and territories across the country in addition to several governmental agencies and 70% of privately insured lives in Canada for private payer health plans reimbursement. Amongst Canadian provinces, territories and governmental agencies presently publicly covering Redesca™ and Redesca HP™ for reimbursement are, Alberta, Manitoba, Ontario, New Brunswick, Prince Edward Island, Newfoundland, Northwest Territories, Non Insured Health Benefits for registered First Nations and recognized Inuit and Veterans Affairs Canada. Public reimbursement coverage in the remaining provinces is anticipated by the end of the year. Redesca is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca has more than 8 years of proven in-market safety internationally. and more than 150 million patient days treated in Europe alone.Recent Insider Transactions • Jul 01Senior VP & CFO recently bought CA$200k worth of stockOn the 29th of June, Luc Mainville bought around 200k shares on-market at roughly CA$1.00 per share. This was the largest purchase by an insider in the last 3 months. Luc has been a buyer over the last 12 months, purchasing a net total of CA$216k worth in shares.Reported Earnings • Jul 01Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.015 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$2.65m (up 27% from 2Q 2020). Net loss: CA$1.87m (loss widened 117% from 2Q 2020).お知らせ • Jun 30Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million.Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 9,000,000 Price\Range: CAD 1 Discount Per Security: CAD 0.07 Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,000,000 Price\Range: CAD 1 Discount Per Security: CAD 0.035お知らせ • Jun 23Valeo Pharma Inc. Announces Commercial Launch of Enerzair Breezhaler and Atectura BreezhalerValeo Pharma Inc. announced that commercialization of Enerzair Breezhaler and Atectura Breezhaler has commenced following product shipments across Canada and the initial deployment of its national respiratory sales force. At present, almost 4 million Canadians are living with asthma1, a serious health issue affecting all age groups. Patients with severe asthma live in fear of potential exacerbations which remain highly prevalent even with today's most advanced therapies. Asthma related exacerbations are concerning because of their associated mortality burden and also because of the increased risk of side effects from the use of systemic corticosteroids. Furthermore, there is growing evidence highlighting the lack of symptom control currently achieved in asthma. 39% of patients remain uncontrolled, despite available dual LABA/ICS medications, primarily due to low adherence, treatment misuse and poor inhaler technique. There is an urgent need to add effective maintenance treatment options to more efficiently address symptoms as well as asthma related long-term complications and mortality.お知らせ • May 27Valeo Pharma Inc. Announces Outlook for Its Second Quarter Ended April 30, 2021Valeo Pharma Inc. announced outlook for its second quarter ended April 30, 2021. The company expects to record revenues, up more than 40% over prior quarter.お知らせ • Apr 28Valeo Pharma Inc. announced that it has received CAD 6.645 million in fundingOn April 27, 2021, Valeo Pharma Inc. (CNSX:VPH) closed the transaction. The company has amended the terms of the transaction. The company issued 6,645 unsecured non-convertible debentures units for gross proceeds of CAD 6,645,000. The transaction included participation from insiders, senior executives, staff members and three directors of the company for CAD 2,600,000. The company has paid finders fees of CAD 38,500 and issued 7,700 broker warrants in relation to the transaction. The securities issued are subject to a hold period of four months from the closing of the transaction.Recent Insider Transactions • Apr 23President recently bought CA$176k worth of stockOn the 15th of April, Frederic Fasano bought around 154k shares on-market at roughly CA$1.14 per share. This was the largest purchase by an insider in the last 3 months. Frederic has been a buyer over the last 12 months, purchasing a net total of CA$199k worth in shares.お知らせ • Apr 16Valeo Pharma Inc. announced that it expects to receive CAD 4 million in fundingValeo Pharma Inc. (CNSX:VPH) announced a non-brokered private placement of up to 4,000 unsecured non-convertible debenture units at a price of CAD 1,000 per debenture unit for maximum gross proceeds of CAD 4,000,000 on April 14, 2021. Each debenture unit will consist of one unsecured non-convertible debenture of the company in the principal amount of CAD 1,000 and 200 class A share purchase warrants. The debentures will mature at least 9 months after the closing and will bear interest at a rate of 8%. Each warrant entitles the holder to purchase one class A share of the company at an exercise price of CAD 0.60 at any time up to 24 months following the closing date. The closing of the transaction is expected to occur on or about April 23, 2021 and is subject to regulatory approval including that of the Canadian Stock Exchange. The Company may pay finder's fees on the non-insider portion of the private placement, in compliance with applicable securities laws. All securities issued in connection with the private placement will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The transaction will include participation from the insiders for CAD 2,600,000.Reported Earnings • Apr 03First quarter 2021 earnings released: CA$0.027 loss per share (vs CA$0.02 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$1.86m (up 11% from 1Q 2020). Net loss: CA$1.73m (loss widened 56% from 1Q 2020).Reported Earnings • Feb 27Full year 2020 earnings released: CA$0.082 loss per share (vs CA$0.073 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CA$7.47m (up 14% from FY 2019). Net loss: CA$4.76m (loss widened 32% from FY 2019).Analyst Estimate Surprise Post Earnings • Feb 27Revenue misses expectationsRevenue missed analyst estimates by 6.6%. Over the next year, revenue is forecast to grow 181%, compared to a 74% growth forecast for the Healthcare industry in Canada.お知らせ • Feb 26Valeo Pharma Inc., Annual General Meeting, Apr 28, 2021Valeo Pharma Inc., Annual General Meeting, Apr 28, 2021. Location: Kirkland Quebec CanadaIs New 90 Day High Low • Feb 26New 90-day low: CA$0.99The company is down 14% from its price of CA$1.15 on 27 November 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 9.0% over the same period.お知らせ • Feb 20Valeo Pharma Inc. to Report Q4, 2020 Results on Feb 24, 2021Valeo Pharma Inc. announced that they will report Q4, 2020 results After-Market on Feb 24, 2021お知らせ • Feb 18Valeo Pharma Inc. and Ingenew Pharma Inc. Announce HespercoTM CapsulesValeo Pharma Inc. and Ingenew Pharma Inc. announced that HespercoTM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute's ("MHI") clinical trial, "The Hesperidin Coronavirus Study". The MHI's study will evaluate the effect of hesperidin on COVID-19 symptoms and its ability to reduce disease severity and the need for hospitalization in patients with COVID-19. The randomized, double-blind, placebo controlled study will enroll 216 confirmed COVID-19 symptomatic patients.分析記事 • Feb 08Have Insiders Been Buying Valeo Pharma Inc. (CSE:VPH) Shares This Year?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...業績と収益の成長予測TSX:VPH - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数10/31/202570N/AN/AN/A110/31/202458N/AN/AN/A17/31/202453-32-7-4N/A4/30/202455-30-10-6N/A1/31/202454-28-8-3N/A10/31/202354-28-21-16N/A7/31/202353-28-20-24N/A4/30/202345-27-32-25N/A1/31/202337-26-37-31N/A10/31/202228-26-35-29N/A7/31/202218-24-33-20N/A4/30/202218-22-25-23N/A1/31/202216-18-22-19N/A10/31/202114-14-16-12N/A7/31/202112-9-14-12N/A4/30/20218-7-10-7N/A1/31/20218-5-8-6N/A10/31/20207-5-7-5N/A7/31/20207-4-5-4N/A4/30/20208-2-5-4N/A1/31/20206-4-5-4N/A10/31/20197-4-3-2N/A7/31/20197-3-3-2N/A4/30/20197-3-2-2N/A1/31/20196-3-2-1N/A10/31/20184-2-2-1N/A7/31/20183-3-1-1N/A10/31/20171-4N/A-1N/A10/31/20161-1N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VPHの予測収益成長が 貯蓄率 ( 2.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: VPHの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: VPHの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: VPHの収益 ( 20.9% ) Canadian市場 ( 4.5% ) よりも速いペースで成長すると予測されています。高い収益成長: VPHの収益 ( 20.9% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VPHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/11/13 11:11終値2024/10/01 00:00収益2024/07/31年間収益2023/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Valeo Pharma Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Scott McAuleyParadigm Capital, Inc.
Price Target Changed • Sep 13Price target decreased by 20% to CA$0.40Down from CA$0.50, the current price target is provided by 1 analyst. New target price is 515% above last closing price of CA$0.065. Stock is down 76% over the past year. The company is forecast to post a net loss per share of CA$0.27 next year compared to a net loss per share of CA$0.32 last year.
Price Target Changed • Feb 05Price target decreased by 12% to CA$0.72Down from CA$0.82, the current price target is an average from 2 analysts. New target price is 179% above last closing price of CA$0.26. Stock is down 57% over the past year. The company is forecast to post a net loss per share of CA$0.21 next year compared to a net loss per share of CA$0.32 last year.
Major Estimate Revision • Feb 05Consensus revenue estimates fall by 14%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CA$74.4m to CA$64.1m. Forecast losses increased from -CA$0.14 to -CA$0.19 per share. Healthcare industry in Canada expected to see average net income growth of 21% next year. Consensus price target reaffirmed at CA$0.82. Share price fell 21% to CA$0.26 over the past week.
Major Estimate Revision • Sep 20Consensus EPS estimates fall by 23%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CA$61.3m to CA$57.6m. Losses expected to increase from CA$0.20 per share to CA$0.25. Healthcare industry in Canada expected to see average net income growth of 17% next year. Consensus price target down from CA$1.47 to CA$0.72. Share price fell 10% to CA$0.27 over the past week.
Price Target Changed • Sep 16Price target decreased by 16% to CA$1.23Down from CA$1.47, the current price target is an average from 3 analysts. New target price is 357% above last closing price of CA$0.27. Stock is down 53% over the past year. The company is forecast to post a net loss per share of CA$0.24 next year compared to a net loss per share of CA$0.32 last year.
Major Estimate Revision • Jul 06Consensus EPS estimates upgraded to CA$0.18 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CA$0.207 to -CA$0.183 per share. Revenue forecast steady at CA$61.2m. Healthcare industry in Canada expected to see average net income growth of 19% next year. Consensus price target of CA$1.48 unchanged from last update. Share price rose 5.3% to CA$0.40 over the past week.
Reported Earnings • Sep 14Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: CA$0.079 loss per share (further deteriorated from CA$0.077 loss in 2Q 2023). Revenue: CA$14.1m (up 4.2% from 2Q 2023). Net loss: CA$7.81m (loss widened 21% from 2Q 2023). Revenue missed analyst estimates by 8.8%. Earnings per share (EPS) also missed analyst estimates by 60%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
Price Target Changed • Sep 13Price target decreased by 20% to CA$0.40Down from CA$0.50, the current price target is provided by 1 analyst. New target price is 515% above last closing price of CA$0.065. Stock is down 76% over the past year. The company is forecast to post a net loss per share of CA$0.27 next year compared to a net loss per share of CA$0.32 last year.
お知らせ • Sep 09Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024Valeo Pharma Inc. announced that they will report Q3, 2024 results After-Market on Sep 12, 2024
お知らせ • Aug 07Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced Mr. Steve Saviuk will remain on the company’s board of directors and assume the role of Chairman. Mr. Richard J. MacKay will step down from his role of chairman of the board and will remain a board member.
お知らせ • Jun 18Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer (CDO) and consequently he is stepping down from the Company's Board of Directors. As Valeo's new CDO, Mr. Moghaddam will lead the design and implementation of strategies to identify and negotiate with financial parties with a view to strengthening the Company's capital structure in order to finance the future growth and development of the Company. He will work directly with the senior management team to plan, review, and revise the company's development programs. Mr. Moghaddam will also support the development and growth of the business through building relationships in the industry, identifying both product and M&A opportunities. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.
New Risk • Jun 17New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$9.2m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-CA$55m). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (CA$10.9m market cap, or US$7.89m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
Reported Earnings • Jun 16Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: CA$0.079 loss per share (further deteriorated from CA$0.077 loss in 2Q 2023). Revenue: CA$14.1m (up 4.2% from 2Q 2023). Net loss: CA$7.81m (loss widened 21% from 2Q 2023). Revenue missed analyst estimates by 8.8%. Earnings per share (EPS) also missed analyst estimates by 60%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
分析記事 • Jun 14Market Might Still Lack Some Conviction On Valeo Pharma Inc. (TSE:VPH) Even After 55% Share Price BoostThose holding Valeo Pharma Inc. ( TSE:VPH ) shares would be relieved that the share price has rebounded 55% in the last...
お知らせ • Jun 06Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024Valeo Pharma Inc. announced that they will report Q2, 2024 results After-Market on Jun 13, 2024
分析記事 • Apr 20Market Cool On Valeo Pharma Inc.'s (TSE:VPH) Revenues Pushing Shares 31% LowerTo the annoyance of some shareholders, Valeo Pharma Inc. ( TSE:VPH ) shares are down a considerable 31% in the last...
New Risk • Apr 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$12.8m (US$9.49m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$8.1m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-CA$47m). Market cap is less than US$10m (CA$12.8m market cap, or US$9.49m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (17% increase in shares outstanding).
お知らせ • Mar 22Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has joined the Company's Board of Directors. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.
Reported Earnings • Mar 15First quarter 2024 earnings releasedFirst quarter 2024 results: Net income: (up CA$6.25m from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.
New Risk • Mar 15New major risk - Revenue and earnings growthEarnings have declined by 50% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$21m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-CA$40m). Earnings have declined by 50% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (CA$19.2m market cap, or US$14.2m).
お知らせ • Mar 08Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024Valeo Pharma Inc. announced that they will report Q1, 2024 results After-Market on Mar 14, 2024
分析記事 • Mar 02Valeo Pharma Inc. (TSE:VPH) Stocks Pounded By 33% But Not Lagging Industry On Growth Or PricingThe Valeo Pharma Inc. ( TSE:VPH ) share price has softened a substantial 33% over the previous 30 days, handing back...
お知らせ • Feb 27Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024.
お知らせ • Feb 13Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company's Board of Directors and that Messrs. Michel Trudeau, Stuart Fowler, Didier Leconte and Ms. Tamara Close have all resigned from its Board of Directors. More about Robert Raich; Prior to establishing RaichLegal Inc, Robert Raich was a senior partner at Spiegel Sohmer Inc., a Montreal firm specializing in taxation law, where he served as managing partner for over 25 years. His areas of expertise include taxation advice for real estate transactions, advice to both purchasers and vendors in acquisitions and sales of businesses, corporate reorganizations, venture capital financing and charitable planning. Mr. Raich graduated from McGill University and was called to the Barreau du Quebec in 1976. He has been recognized on several occasions as one of the Best Lawyers in Canada in the fields of Taxation law and Law of Estates and Trusts in Canada and has been a frequent guest lecturer at McGill University Faculty of Law and tax conferences. More about Charles Bisaillon; Charles Bisaillon is an entrepreneurial-minded leader who loves rapidly scaling organizations in both wholesale & direct-to-consumer channels. Charles is currently President and owner of Airtek Ltée, a leading Canadian manufacturing company, established in Montreal Quebec since 1970. Charles is also the Chief Financial Officer Groupe J.B a residential, commercial & institutional construction company. Mr. Bisaillon graduated from l'École des sciences de la gestion, UQAM. He is a chartered professional accountant of Canada (CPA Canada).
Price Target Changed • Feb 05Price target decreased by 12% to CA$0.72Down from CA$0.82, the current price target is an average from 2 analysts. New target price is 179% above last closing price of CA$0.26. Stock is down 57% over the past year. The company is forecast to post a net loss per share of CA$0.21 next year compared to a net loss per share of CA$0.32 last year.
Major Estimate Revision • Feb 05Consensus revenue estimates fall by 14%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CA$74.4m to CA$64.1m. Forecast losses increased from -CA$0.14 to -CA$0.19 per share. Healthcare industry in Canada expected to see average net income growth of 21% next year. Consensus price target reaffirmed at CA$0.82. Share price fell 21% to CA$0.26 over the past week.
Reported Earnings • Jan 30Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: CA$0.32 loss per share (further deteriorated from CA$0.32 loss in FY 2022). Revenue: CA$53.9m (up 94% from FY 2022). Net loss: CA$27.8m (loss widened 8.0% from FY 2022). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 12%. Over the last 3 years on average, earnings per share has fallen by 40% per year whereas the company’s share price has fallen by 38% per year.
お知らせ • Jan 23Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024Valeo Pharma Inc. announced that they will report Q4, 2023 results After-Market on Jan 29, 2024
分析記事 • Jan 17Investors Still Aren't Entirely Convinced By Valeo Pharma Inc.'s (TSE:VPH) Revenues Despite 68% Price JumpValeo Pharma Inc. ( TSE:VPH ) shares have continued their recent momentum with a 68% gain in the last month alone. Not...
New Risk • Jan 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 17% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$35m). Negative equity (-CA$35m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Share price has been volatile over the past 3 months (17% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$23.2m market cap, or US$17.2m). Market cap is less than US$100m (CA$23.2m market cap, or US$17.2m).
お知らせ • Nov 21Valeo Pharma Inc. Announces Chief Financial Officer ChangesValeo Pharma Inc. announced the appointment of Mr. Pascal Tougas to the position of Chief Financial Officer, effective November 20, 2023. Joining the Valeo leadership team, Mr. Tougas will succeed Luc Mainville, who is leaving the Company after 5 years to pursue other ventures. Pascal is a seasoned senior pharmaceutical executive with a strong finance profile. With a passion for driving value in organizations, Pascal has a track record of collaboration, forward strategic thinking, operational and financial business acumen, and execution. Pascal spent 11 years at Sanofi Canada in roles of increasing responsibility where he served as Country Head, Trade and Revenue Management, Chief Financial Officer Canada interim and Director Controlling and Operations Canada amongst others. Pascal holds a bachelor's degree in business administration from the HEC Montreal and a CPA designation.
お知らせ • Nov 08Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of DirectorsValeo Pharma Inc. announced that Mr. Richard Lajoie has joined the Company's Board of Directors and that Ms. Maureen C. Brennan has retired from its Board of Directors. ichard Lajoie has been recognized over the last 24 years as an inspirational and creative leader with a strong capacity to build high performing teams. Richard was President of Bausch Health, Canada from 2017 to 2021 before being promoted to President Ortho Dermatologics US based in New Jersey. He has led innovative business model transformations, many new launches and completed successful business development deals. Prior to Bausch Health, Richard spent 12 years with Novartis Pharmaceuticals in roles of increasing responsibility (Sales, Marketing, Government Affairs and Medical) located in Montreal, Calgary and Copenhagen where he led Denmark, Norway and Iceland as General Manager for Novartis Oncology.
New Risk • Oct 31New major risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: CA$13.8m (US$9.99m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Negative equity (-CA$35m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$13.8m market cap, or US$9.99m).
New Risk • Oct 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$28m Forecast net loss in 1 year: CA$17m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-CA$35m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$16.8m market cap, or US$12.3m).
Major Estimate Revision • Sep 20Consensus EPS estimates fall by 23%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CA$61.3m to CA$57.6m. Losses expected to increase from CA$0.20 per share to CA$0.25. Healthcare industry in Canada expected to see average net income growth of 17% next year. Consensus price target down from CA$1.47 to CA$0.72. Share price fell 10% to CA$0.27 over the past week.
Price Target Changed • Sep 16Price target decreased by 16% to CA$1.23Down from CA$1.47, the current price target is an average from 3 analysts. New target price is 357% above last closing price of CA$0.27. Stock is down 53% over the past year. The company is forecast to post a net loss per share of CA$0.24 next year compared to a net loss per share of CA$0.32 last year.
Reported Earnings • Sep 15Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: CA$0.069 loss per share (further deteriorated from CA$0.058 loss in 3Q 2022). Revenue: CA$14.1m (up 132% from 3Q 2022). Net loss: CA$5.84m (loss widened 23% from 3Q 2022). Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 08Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023Valeo Pharma Inc. announced that they will report Q3, 2023 results After-Market on Sep 13, 2023
お知らせ • Sep 01Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement QuébecValeo Pharma Inc. announced a non-brokered private placement of 13,999,997 units of the company at a price of CAD 0.28 per unit for gross proceeds of CAD 3,919,999 and entered into a loan agreement with a related party for a principal amount of CAD 580,000 bearing annual interest at a rate of 12%; for aggregate total gross proceeds of CAD 4,499,999 on August 31, 2023. The transaction included participation from Investissement Québec for CAD 2 million and insiders for CAD 1,421,000. Each unit consist of one class A share of the company and one-half share purchase warrant of the company. Each full warrant entitles the holder to purchase one share in the capital of the company at the price of CAD 0.35 per warrant share for a period of 60 months from the closing date of the transaction. In the event that the daily volume weighted average trading price of the shares over any ten consecutive trading days is greater or equal to CAD 0.70, the company may give notice to the warrant holder, at any time after the first 12 months following the closing, that all outstanding warrants must be exercised within a period of 30 days from the date of receipt of the notice, failing which the warrants will automatically expire. The common shares and the warrants are subject to a statutory 4 month hold period under the applicable securities laws.
Major Estimate Revision • Jul 06Consensus EPS estimates upgraded to CA$0.18 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CA$0.207 to -CA$0.183 per share. Revenue forecast steady at CA$61.2m. Healthcare industry in Canada expected to see average net income growth of 19% next year. Consensus price target of CA$1.48 unchanged from last update. Share price rose 5.3% to CA$0.40 over the past week.
Board Change • Jun 29Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Marc Leger was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 23Valeo Pharma Inc. Announces Board AppointmentsValeo Pharma Inc. announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the appointment of Ms. Close and Mr. Leconte, Valeo's Board of Directors is now comprised of 8 Directors, 5 of whom are independent. Ms. Close is a senior investment and Environmental, Social and Governance (ESG) professional with over 25 years of experience in capital markets, with roles spanning sell-side trading and institutional sales to buy-side research, risk management and strategy. She is the founder and managing partner of Close Group Consulting, an independent, boutique ESG advisory firm headquartered in Montreal, with offices in Toronto, Boston, and London (UK). Tamara is a sought-after speaker and regularly publishes ESG thought leadership and research. Ms. Close holds an M.Sc. Finance from Concordia University with a B.A. Economics from McGill University and is a Chartered Financial Analyst (CFA). Mr. Didier Leconte is a highly experienced investor and Canadian life sciences leader. He has deep commercial experience in Canada and Québec's technology transfer and investment arenas. With a strong dedication to the development of Québec's and Canada's life sciences industries, Didier served as Vice-president, Life Science & Technology for Investissement Quebec and Vice-president Life Sciences at Fonds de solidarité FTQ. Mr. Leconte holds a MBA, Technology Management & Innovation from the Université du Québec à Montréal, a certification in governance from Université Laval and an engineering degree in Material Sciences from École d'ingénieurs Sup Galilée, Institut Galilée, Université Sorbonne Paris Nord.
Breakeven Date Change • Jun 17Forecast breakeven date pushed back to 2025The 4 analysts covering Valeo Pharma previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 85% per year to 2024. The company is expected to make a profit of CA$13.5m in 2025. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Reported Earnings • Jun 15Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: CA$0.077 loss per share (further deteriorated from CA$0.063 loss in 2Q 2022). Revenue: CA$13.6m (up 184% from 2Q 2022). Net loss: CA$6.48m (loss widened 27% from 2Q 2022). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 09Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023Valeo Pharma Inc. announced that they will report Q2, 2023 results After-Market on Jun 13, 2023
分析記事 • Jun 08Valeo Pharma Inc. (TSE:VPH) Might Not Be As Mispriced As It Looks After Plunging 29%To the annoyance of some shareholders, Valeo Pharma Inc. ( TSE:VPH ) shares are down a considerable 29% in the last...
Reported Earnings • Mar 17First quarter 2023 earnings: EPS misses analyst expectationsFirst quarter 2023 results: CA$0.077 loss per share (further deteriorated from CA$0.074 loss in 1Q 2022). Revenue: CA$13.2m (up 210% from 1Q 2022). Net loss: CA$6.25m (loss widened 6.6% from 1Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.7%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
Recent Insider Transactions Derivative • Mar 02Independent Director exercised options to buy CA$151k worth of stock.On the 27th of February, Vincent Hogue exercised options to buy 265k shares at a strike price of around CA$0.40, costing a total of CA$106k. This transaction amounted to 105% of their direct individual holding at the time of the trade. Since March 2022, Vincent has owned 252.41k shares directly. Company insiders have collectively bought CA$2.5b more than they sold, via options and on-market transactions, in the last 12 months.
お知らせ • Feb 08Valeo Pharma Obtains Public Reimbursement for Onstryv in QuebecValeo Pharma Inc. announced that Onstryv (safinamide) for the treatment of patients suffering from Parkinson's disease, is now listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Quebec Régie de l'assurance maladie du Québec ("RAMQ"), effective February 1, 2023. Onstryv® is approved by Health Canada as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's Disease in patients experiencing "off" episodes. Onstryvâ is a prescription medication available at pharmacies across Canada in 50mg and 100mg tablets. Parkinson's Disease is a progressive neurological disease involving the loss of dopamine producing neurons in the brain. While tremors are the best known symptom, Parkinson's Disease also causes other symptoms including slowed movement, rigid muscles, impaired posture and balance, speech and writing difficulties. On a per capita basis, Canada has amongst the higher incidences of Parkinson's Disease in the world and the number of patients is expected to grow significantly over the next thirty years as the median population age increases. Safinamide, known as Onstryv® in Canada and Xadago® in the rest of the world, is a chemical entity with a unique mode of action including selective and reversible MAO-B inhibition. Clinical trials have established its efficacy in controlling motor symptoms and motor complications in the short term, maintaining this effect over 2 years. Results from 24 month double-blind controlled studies suggest that safinamide shows statistically significant effects on motor fluctuations (ON/OFF time) without increasing the risk of developing troublesome dyskinesia. Onstryv® is a once-daily dose and has no diet restrictions due to its high MAO-B/MAO-A selectivity.
Major Estimate Revision • Feb 06Consensus EPS estimates fall by 31%The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -CA$0.17 per share expected, vs -CA$0.13 per share profit forecast previously. Revenue forecast reaffirmed at CA$64.5m. Healthcare industry in Canada expected to see average net income growth of 4.6% next year. Consensus price target of CA$1.63 unchanged from last update. Share price fell 6.3% to CA$0.59 over the past week.
Reported Earnings • Feb 01Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: CA$0.32 loss per share (further deteriorated from CA$0.20 loss in FY 2021). Revenue: CA$27.7m (up 105% from FY 2021). Net loss: CA$25.7m (loss widened 81% from FY 2021). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 33%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
お知らせ • Jan 27Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 PatientsValeo Pharma Inc. announced that Health Canada has accepted for review Veru's New Drug Submission ("NDS-CV") for sabizabulin for COVID-19. Sabizabulin is a novel dual antiviral and anti-inflammatory agent being developed for the treatment of hospitalized moderate to severe COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS) and death. The Phase 3 COVID-19 clinical trial of sabizabulin was a double-blind, randomized, placebo controlled trial conducted in 204 hospitalized COVID-19 patients with moderate to severe COVID-19 (= WHO 4-supplemental oxygen) at high risk for ARDS and death. The primary endpoint was the proportion of deaths by Day 60. Patients in both treatment groups were allowed to receive standard of care treatment, including remdesivir, dexamethasone, anti-IL6 receptor antibodies and JAK inhibitors. Based on a planned interim analysis of the first 150 patients randomized, the Independent Data Monitoring Committee unanimously recommended to halt the study early for clear clinical efficacy and no safety concerns were identified. Treatment with sabizabulin 9 mg once daily, an oral, first-in-class, new chemical entity, microtubule disruptor that has dual anti-inflammatory and antiviral properties, resulted in a clinically meaningful and statistically significant 55.2% relative reduction in deaths compared to placebo. The results of the interim analysis were published in The New England Journal of Medicine (NEJM) Evidence. In the final analysis of all 204 patients, sabizabulin demonstrated a statistically significant 51.6% relative reduction in deaths compared to placebo. Sabizabulin was well tolerated. Valeo previously announced in September 2022 that Veru and Valeo had entered into an agreement under which Valeo is the commercial partner for Veru's product candidate sabizabulin for COVID-19 in Canada.
お知らせ • Jan 26Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023Valeo Pharma Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 30, 2023
お知らせ • Nov 22Valeo Pharma Inc. Announces Stepping Down of Frederic Fasano as President and Chief Operating OfficerValeo Pharma Inc. announced that Mr. Frederic Fasano has stepped down as Valeo's President and Chief Operating Officer. Mr. Fasano will continue to act as special advisor to the Company and will remain on the Board of Directors. Mr. Fasano's duties and responsibilities are being integrated and assumed by the Company's CEO, Steve Saviuk and its Chief Commercial Officer, Mr. Kyle Steiger.
お知らせ • Nov 16+ 1 more updateValeo Pharma Inc. Revises Revenue Guidance for the Fourth Quarter of 2022Valeo Pharma Inc. revised revenue guidance for the fourth quarter of 2022. The company has raised revenue guidance for its fourth quarter of 2022 to $12.5 - $13.0 million, an increase of 14% to 18% over previously issued guidance of $11 million.
Price Target Changed • Nov 16Price target increased to CA$1.63Up from CA$1.33, the current price target is an average from 3 analysts. New target price is 159% above last closing price of CA$0.63. Stock is down 18% over the past year. The company is forecast to post a net loss per share of CA$0.25 next year compared to a net loss per share of CA$0.20 last year.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Michel Trudeau was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 16Valeo Pharma Inc. Provides Revenue Guidance for the Fourth Quarter of 2022Valeo Pharma Inc. provided revenue guidance for the fourth quarter of 2022. The company expects revenues in the fourth quarter to exceed $11 million.
Reported Earnings • Sep 14Third quarter 2022 earnings: EPS misses analyst expectationsThird quarter 2022 results: CA$0.058 loss per share (further deteriorated from CA$0.042 loss in 3Q 2021). Revenue: CA$6.07m (up 7.2% from 3Q 2021). Net loss: CA$4.74m (loss widened 60% from 3Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
お知らせ • Sep 10Valeo Pharma Inc. to Report Q3, 2022 Results on Sep 13, 2022Valeo Pharma Inc. announced that they will report Q3, 2022 results After-Market on Sep 13, 2022
お知らせ • Aug 31Valeo Pharma Announces Executive AppointmentsValeo Pharma Inc. announced the appointment of Mr. Kyle Steiger to the role of Senior Vice-President and Chief Commercial Officer ("CCO"). Mr. Steiger is a pharmaceutical industry veteran whose diverse work experience includes specialty pharma, biologics, primary care, medical devices, OTC, health policy and market access. He spent nearly 20 years at Novartis Canada in various executive positions including Franchise Head Hematology, Vice-President Primary Care and most recently Vice-President Ophthalmology. Valeo also announced that Mr. Jean-François Fournier has joined as its new Business Unit Head – Ophthalmology. Prior to joining Valeo, Jean-François served as Commercial Director – Marketing & Sales at Novartis Canada.
分析記事 • Jun 24Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%The analysts covering Valeo Pharma Inc. ( TSE:VPH ) delivered a dose of negativity to shareholders today, by making a...
Major Estimate Revision • Jun 21Consensus revenue estimates fall by 24%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from CA$36.0m to CA$27.3m. Forecast losses increased from -CA$0.17 to -CA$0.23 per share. Healthcare industry in Canada expected to see average net income growth of 6.8% next year. Consensus price target down from CA$1.70 to CA$1.33. Share price rose 19% to CA$0.62 over the past week.
Recent Insider Transactions • Jun 19Key Executive recently bought CA$113k worth of stockOn the 16th of June, Richard MacKay bought around 217k shares on-market at roughly CA$0.52 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$816k worth in shares.
分析記事 • Jun 17Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their ForecastsIt's been a pretty great week for Valeo Pharma Inc. ( TSE:VPH ) shareholders, with its shares surging 12% to CA$0.56 in...
Breakeven Date Change • Jun 17No longer forecast to breakevenThe 3 analysts covering Valeo Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CA$2.96m in 2023. New consensus forecast suggests the company will make a loss of CA$1.82m in 2024.
Reported Earnings • Jun 15Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: CA$0.063 loss per share (down from CA$0.028 loss in 2Q 2021). Revenue: CA$4.77m (up 80% from 2Q 2021). Net loss: CA$5.10m (loss widened 173% from 2Q 2021). Revenue missed analyst estimates by 27%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 204%, compared to a 22% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 09Valeo Pharma Inc. to Report Q2, 2022 Results on Jun 14, 2022Valeo Pharma Inc. announced that they will report Q2, 2022 results After-Market on Jun 14, 2022
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Michel Trudeau was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Apr 27Price target decreased to CA$1.70Down from CA$1.87, the current price target is an average from 3 analysts. New target price is 227% above last closing price of CA$0.52. Stock is down 56% over the past year. The company is forecast to post a net loss per share of CA$0.17 next year compared to a net loss per share of CA$0.20 last year.
Major Estimate Revision • Mar 31Consensus EPS estimates fall by 42%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CA$38.1m to CA$36.0m. Losses expected to increase from CA$0.12 per share to CA$0.17. Healthcare industry in Canada expected to see average net income growth of 5.0% next year. Consensus price target of CA$1.70 unchanged from last update. Share price fell 4.4% to CA$0.65 over the past week.
Recent Insider Transactions Derivative • Mar 12Key Executive exercised options to buy CA$1.5m worth of stock.On the 4th of March, Richard MacKay exercised options to buy 3m shares at a strike price of around CA$0.40, costing a total of CA$1.0m. This transaction amounted to 30% of their direct individual holding at the time of the trade. Since March 2021, Richard's direct individual holding has increased from 8.15m shares to 8.76m. Company insiders have collectively bought CA$2.5m more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CA$0.20 loss per share (down from CA$0.082 loss in FY 2020). Revenue: CA$13.6m (up 82% from FY 2020). Net loss: CA$14.2m (loss widened 199% from FY 2020). Revenue missed analyst estimates by 7.1%. Over the next year, revenue is forecast to grow 174%, compared to a 33% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 26Valeo Pharma Inc., Annual General Meeting, Apr 27, 2022Valeo Pharma Inc., Annual General Meeting, Apr 27, 2022.
お知らせ • Feb 22Valeo Pharma Inc. to Report Q4, 2021 Results on Feb 28, 2022Valeo Pharma Inc. announced that they will report Q4, 2021 results After-Market on Feb 28, 2022
Price Target Changed • Jan 12Price target decreased to CA$1.77Down from CA$1.97, the current price target is an average from 3 analysts. New target price is 145% above last closing price of CA$0.72. Stock is down 43% over the past year. The company is forecast to post a net loss per share of CA$0.15 next year compared to a net loss per share of CA$0.082 last year.
お知らせ • Jan 06Valeo Pharma's Hespercotm Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted for PublicationValeo Pharma Inc. announced that Hesperco, its unique flavonoid formulation approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw's banners including Loblaws, Dominion, Zehrs, Fortinio's, Your Independent Grocer and Superstore.
お知らせ • Nov 25Valeo Pharma Inc. announced that it expects to receive CAD 20 million in funding from Investissement Québec, Investment Arm and other investorsValeo Pharma Inc. announced a bought deal private placement of 10,000 convertible unsecured debentures at a price of CAD 1,000 per debenture for gross proceeds of CAD 10,000,000 and private placement of 10,000 convertible unsecured debentures at a price of CAD 1,000 per debenture for gross proceeds of CAD 10,000,000 to Investissement Québec, Investment Arm for aggregate gross proceeds of CAD 20,000,000 on November 24, 2021. The debentures are being issued at par. The debentures will mature on December 31, 2024 and will accrue interest at the rate of 12% per annum, payable quarterly beginning on March 31, 2022. At the holders' option, the debentures may be converted into common shares of the company at any time and from time to time, up to the maturity date, at a conversion price of CAD 1.15 per common share. The company has granted the underwriters an option to purchase up to an additional CAD 1,500,000 aggregate principal amount of debentures, exercisable at any time up to 48 hours prior to the closing. The closing is expected to occur on or about December 9, 2021 and is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange. The company will use commercially reasonable efforts to list the debentures on the Canadian Securities Exchange. The debentures and any common shares issuable upon conversion thereof will be subject to a statutory hold period lasting four months and one day following the closing date.
Recent Insider Transactions • Oct 23Key Executive recently bought CA$90k worth of stockOn the 20th of October, Richard MacKay bought around 100k shares on-market at roughly CA$0.90 per share. In the last 3 months, they made an even bigger purchase worth CA$360k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$703k worth in shares.
Recent Insider Transactions • Oct 08Key Executive recently bought CA$75k worth of stockOn the 1st of October, Richard MacKay bought around 100k shares on-market at roughly CA$0.75 per share. In the last 3 months, there was an even bigger purchase from another insider worth CA$100k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$253k worth in shares.
Recent Insider Transactions • Oct 02Key Executive recently bought CA$78k worth of stockOn the 27th of September, Richard MacKay bought around 109k shares on-market at roughly CA$0.72 per share. In the last 3 months, there was an even bigger purchase from another insider worth CA$100k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$178k worth in shares.
Reported Earnings • Sep 24Third quarter 2021 earnings released: CA$0.042 loss per share (vs CA$0.028 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: CA$5.67m (up 280% from 3Q 2020). Net loss: CA$2.97m (loss widened 84% from 3Q 2020).
Recent Insider Transactions • Jul 18Senior VP & CFO recently bought CA$100k worth of stockOn the 15th of July, Luc Mainville bought around 150k shares on-market at roughly CA$0.67 per share. In the last 3 months, they made an even bigger purchase worth CA$200k. Luc has been a buyer over the last 12 months, purchasing a net total of CA$316k worth in shares.
お知らせ • Jul 15Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™Valeo Pharma Inc. announced that Redesca™ and Redesca HP™, its low molecular weight heparin ("LMWH") biosimilar, is now covered for public reimbursement in 7 provinces and territories across the country in addition to several governmental agencies and 70% of privately insured lives in Canada for private payer health plans reimbursement. Amongst Canadian provinces, territories and governmental agencies presently publicly covering Redesca™ and Redesca HP™ for reimbursement are, Alberta, Manitoba, Ontario, New Brunswick, Prince Edward Island, Newfoundland, Northwest Territories, Non Insured Health Benefits for registered First Nations and recognized Inuit and Veterans Affairs Canada. Public reimbursement coverage in the remaining provinces is anticipated by the end of the year. Redesca is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca has more than 8 years of proven in-market safety internationally. and more than 150 million patient days treated in Europe alone.
Recent Insider Transactions • Jul 01Senior VP & CFO recently bought CA$200k worth of stockOn the 29th of June, Luc Mainville bought around 200k shares on-market at roughly CA$1.00 per share. This was the largest purchase by an insider in the last 3 months. Luc has been a buyer over the last 12 months, purchasing a net total of CA$216k worth in shares.
Reported Earnings • Jul 01Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.015 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$2.65m (up 27% from 2Q 2020). Net loss: CA$1.87m (loss widened 117% from 2Q 2020).
お知らせ • Jun 30Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million.Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 9,000,000 Price\Range: CAD 1 Discount Per Security: CAD 0.07 Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,000,000 Price\Range: CAD 1 Discount Per Security: CAD 0.035
お知らせ • Jun 23Valeo Pharma Inc. Announces Commercial Launch of Enerzair Breezhaler and Atectura BreezhalerValeo Pharma Inc. announced that commercialization of Enerzair Breezhaler and Atectura Breezhaler has commenced following product shipments across Canada and the initial deployment of its national respiratory sales force. At present, almost 4 million Canadians are living with asthma1, a serious health issue affecting all age groups. Patients with severe asthma live in fear of potential exacerbations which remain highly prevalent even with today's most advanced therapies. Asthma related exacerbations are concerning because of their associated mortality burden and also because of the increased risk of side effects from the use of systemic corticosteroids. Furthermore, there is growing evidence highlighting the lack of symptom control currently achieved in asthma. 39% of patients remain uncontrolled, despite available dual LABA/ICS medications, primarily due to low adherence, treatment misuse and poor inhaler technique. There is an urgent need to add effective maintenance treatment options to more efficiently address symptoms as well as asthma related long-term complications and mortality.
お知らせ • May 27Valeo Pharma Inc. Announces Outlook for Its Second Quarter Ended April 30, 2021Valeo Pharma Inc. announced outlook for its second quarter ended April 30, 2021. The company expects to record revenues, up more than 40% over prior quarter.
お知らせ • Apr 28Valeo Pharma Inc. announced that it has received CAD 6.645 million in fundingOn April 27, 2021, Valeo Pharma Inc. (CNSX:VPH) closed the transaction. The company has amended the terms of the transaction. The company issued 6,645 unsecured non-convertible debentures units for gross proceeds of CAD 6,645,000. The transaction included participation from insiders, senior executives, staff members and three directors of the company for CAD 2,600,000. The company has paid finders fees of CAD 38,500 and issued 7,700 broker warrants in relation to the transaction. The securities issued are subject to a hold period of four months from the closing of the transaction.
Recent Insider Transactions • Apr 23President recently bought CA$176k worth of stockOn the 15th of April, Frederic Fasano bought around 154k shares on-market at roughly CA$1.14 per share. This was the largest purchase by an insider in the last 3 months. Frederic has been a buyer over the last 12 months, purchasing a net total of CA$199k worth in shares.
お知らせ • Apr 16Valeo Pharma Inc. announced that it expects to receive CAD 4 million in fundingValeo Pharma Inc. (CNSX:VPH) announced a non-brokered private placement of up to 4,000 unsecured non-convertible debenture units at a price of CAD 1,000 per debenture unit for maximum gross proceeds of CAD 4,000,000 on April 14, 2021. Each debenture unit will consist of one unsecured non-convertible debenture of the company in the principal amount of CAD 1,000 and 200 class A share purchase warrants. The debentures will mature at least 9 months after the closing and will bear interest at a rate of 8%. Each warrant entitles the holder to purchase one class A share of the company at an exercise price of CAD 0.60 at any time up to 24 months following the closing date. The closing of the transaction is expected to occur on or about April 23, 2021 and is subject to regulatory approval including that of the Canadian Stock Exchange. The Company may pay finder's fees on the non-insider portion of the private placement, in compliance with applicable securities laws. All securities issued in connection with the private placement will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The transaction will include participation from the insiders for CAD 2,600,000.
Reported Earnings • Apr 03First quarter 2021 earnings released: CA$0.027 loss per share (vs CA$0.02 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$1.86m (up 11% from 1Q 2020). Net loss: CA$1.73m (loss widened 56% from 1Q 2020).
Reported Earnings • Feb 27Full year 2020 earnings released: CA$0.082 loss per share (vs CA$0.073 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CA$7.47m (up 14% from FY 2019). Net loss: CA$4.76m (loss widened 32% from FY 2019).
Analyst Estimate Surprise Post Earnings • Feb 27Revenue misses expectationsRevenue missed analyst estimates by 6.6%. Over the next year, revenue is forecast to grow 181%, compared to a 74% growth forecast for the Healthcare industry in Canada.
お知らせ • Feb 26Valeo Pharma Inc., Annual General Meeting, Apr 28, 2021Valeo Pharma Inc., Annual General Meeting, Apr 28, 2021. Location: Kirkland Quebec Canada
Is New 90 Day High Low • Feb 26New 90-day low: CA$0.99The company is down 14% from its price of CA$1.15 on 27 November 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 9.0% over the same period.
お知らせ • Feb 20Valeo Pharma Inc. to Report Q4, 2020 Results on Feb 24, 2021Valeo Pharma Inc. announced that they will report Q4, 2020 results After-Market on Feb 24, 2021
お知らせ • Feb 18Valeo Pharma Inc. and Ingenew Pharma Inc. Announce HespercoTM CapsulesValeo Pharma Inc. and Ingenew Pharma Inc. announced that HespercoTM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute's ("MHI") clinical trial, "The Hesperidin Coronavirus Study". The MHI's study will evaluate the effect of hesperidin on COVID-19 symptoms and its ability to reduce disease severity and the need for hospitalization in patients with COVID-19. The randomized, double-blind, placebo controlled study will enroll 216 confirmed COVID-19 symptomatic patients.
分析記事 • Feb 08Have Insiders Been Buying Valeo Pharma Inc. (CSE:VPH) Shares This Year?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...